ACM
RARE icon

Aster Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aster Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.65K Sell
259
-314
-55% -$7.8K ﹤0.01% 675
2026
Q1 		$20.7K Sell
573
-1,870
-77% -$42.1K 0.01% 549
2025
Q4 		$56.2K Buy
+2,443
New +$80.3K 0.02% 445
2025
Q1 		– Sell
-825
Closed -$34.7K – 1603
2024
Q4 		$34.7K Buy
+825
New +$40.9K 0.01% 549

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Aster Capital Management's RARE Position: Q2 2026 in Review

Aster Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 55% in Q2 2026, selling an estimated $7.8K and leaving 259 shares worth $8.65K. The position accounts for ﹤0.01% of the portfolio, ranked #675.

Aster Capital Management first reported a position in RARE in Q4 2024 and has held it in 4 quarters since. The position peaked at $56.2K in Q4 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Aster Capital Management held 259 shares of Ultragenyx Pharmaceutical worth $8.65K as of Q2 2026.
  • Aster Capital Management sold 314 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $7.8K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #675 holding.
  • Aster Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 4 quarters since.
  • Aster Capital Management's Ultragenyx Pharmaceutical position peaked at $56.2K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.